169.81 USD
+0.8 (+0.47%)
169.81 USD
0 (0%)
Overall LHCG gets a fundamental rating of 4 out of 10. We evaluated LHCG against 101 industry peers in the Health Care Providers & Services industry. LHCG has an average financial health and profitability rating. LHCG is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year LHCG was profitable.
In the past year LHCG has reported a negative cash flow from operations.
1.2 Ratios
LHCG's Return On Assets of 2.16% is fine compared to the rest of the industry. LHCG outperforms 66.09% of its industry peers.
LHCG has a Return On Equity of 3.94%. This is in the better half of the industry: LHCG outperforms 66.09% of its industry peers.
The Return On Invested Capital of LHCG (4.20%) is better than 62.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.16% | ||
| ROE | 3.94% | ||
| ROIC | 4.2% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of LHCG (2.73%) is better than 65.22% of its industry peers.
LHCG's Profit Margin has improved in the last couple of years.
LHCG has a Operating Margin of 6.15%. This is in the better half of the industry: LHCG outperforms 68.70% of its industry peers.
LHCG's Operating Margin has improved in the last couple of years.
LHCG's Gross Margin of 38.62% is fine compared to the rest of the industry. LHCG outperforms 68.70% of its industry peers.
In the last couple of years the Gross Margin of LHCG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.15% | ||
| PM (TTM) | 2.73% | ||
| GM | 38.62% |
OM growth 3Y2.47%
OM growth 5Y2.07%
PM growth 3Y14.06%
PM growth 5Y5.1%
GM growth 3Y3.28%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LHCG is destroying value.
Compared to 1 year ago, LHCG has less shares outstanding
The debt/assets ratio for LHCG is higher compared to a year ago.
2.2 Solvency
LHCG has an Altman-Z score of 3.80. This indicates that LHCG is financially healthy and has little risk of bankruptcy at the moment.
LHCG has a better Altman-Z score (3.80) than 80.87% of its industry peers.
LHCG has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LHCG (0.46) is better than 64.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.8 |
ROIC/WACC0.5
WACC8.35%
2.3 Liquidity
LHCG has a Current Ratio of 1.45. This is a normal value and indicates that LHCG is financially healthy and should not expect problems in meeting its short term obligations.
LHCG has a Current ratio of 1.45. This is comparable to the rest of the industry: LHCG outperforms 54.78% of its industry peers.
LHCG has a Quick Ratio of 1.45. This is a normal value and indicates that LHCG is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.45, LHCG is doing good in the industry, outperforming 61.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.45 |
3. Growth
3.1 Past
LHCG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.09%.
Measured over the past years, LHCG shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.42% on average per year.
Looking at the last year, LHCG shows a small growth in Revenue. The Revenue has grown by 6.44% in the last year.
LHCG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.79% yearly.
EPS 1Y (TTM)-25.09%
EPS 3Y18.36%
EPS 5Y22.42%
EPS Q2Q%-26.9%
Revenue 1Y (TTM)6.44%
Revenue growth 3Y7.04%
Revenue growth 5Y19.79%
Sales Q2Q%2.03%
3.2 Future
LHCG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.16% yearly.
LHCG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.06% yearly.
EPS Next Y-22.68%
EPS Next 2Y-7.47%
EPS Next 3Y-2.14%
EPS Next 5Y3.16%
Revenue Next Year4.9%
Revenue Next 2Y5.12%
Revenue Next 3Y5.4%
Revenue Next 5Y7.06%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 38.68 indicates a quite expensive valuation of LHCG.
LHCG's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 25.47, LHCG is valued quite expensively.
LHCG is valuated quite expensively with a Price/Forward Earnings ratio of 34.68.
Based on the Price/Forward Earnings ratio, LHCG is valued a bit cheaper than the industry average as 61.74% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of LHCG to the average of the S&P500 Index (34.42), we can say LHCG is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.68 | ||
| Fwd PE | 34.68 |
4.2 Price Multiples
LHCG's Enterprise Value to EBITDA is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 36.27 |
4.3 Compensation for Growth
A cheap valuation may be justified as LHCG's earnings are expected to decrease with -2.14% in the coming years.
PEG (NY)N/A
PEG (5Y)1.72
EPS Next 2Y-7.47%
EPS Next 3Y-2.14%
5. Dividend
5.1 Amount
No dividends for LHCG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
169.81
+0.8 (+0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.38%
Ins Owner Change0%
Market Cap5.27B
Revenue(TTM)2.31B
Net Income(TTM)63.04M
Analysts52.31
Price Target176.8 (4.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.89%
Min EPS beat(2)-28.55%
Max EPS beat(2)-21.23%
EPS beat(4)1
Avg EPS beat(4)-13.67%
Min EPS beat(4)-28.55%
Max EPS beat(4)1.37%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.18%
Min Revenue beat(2)-7.57%
Max Revenue beat(2)-6.79%
Revenue beat(4)0
Avg Revenue beat(4)-4.6%
Min Revenue beat(4)-7.57%
Max Revenue beat(4)-1.81%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.68 | ||
| Fwd PE | 34.68 | ||
| P/S | 2.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 36.27 |
EPS(TTM)4.39
EY2.59%
EPS(NY)4.9
Fwd EY2.88%
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS74.37
BVpS51.57
TBVpS-17.57
PEG (NY)N/A
PEG (5Y)1.72
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.16% | ||
| ROE | 3.94% | ||
| ROCE | N/A | ||
| ROIC | 4.2% | ||
| ROICexc | 4.22% | ||
| ROICexgc | 24.13% | ||
| OM | 6.15% | ||
| PM (TTM) | 2.73% | ||
| GM | 38.62% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)7.29%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-4.92%
ROICexgc growth 5Y0.12%
ROICexc growth 3Y-3.77%
ROICexc growth 5Y-10.17%
OM growth 3Y2.47%
OM growth 5Y2.07%
PM growth 3Y14.06%
PM growth 5Y5.1%
GM growth 3Y3.28%
GM growth 5Y0.9%
F-Score3
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.46 | ||
| Cap/Depr | 100.43% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.45 | ||
| Altman-Z | 3.8 |
F-Score3
WACC8.35%
ROIC/WACC0.5
Cap/Depr(3y)217.37%
Cap/Depr(5y)282.31%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.09%
EPS 3Y18.36%
EPS 5Y22.42%
EPS Q2Q%-26.9%
EPS Next Y-22.68%
EPS Next 2Y-7.47%
EPS Next 3Y-2.14%
EPS Next 5Y3.16%
Revenue 1Y (TTM)6.44%
Revenue growth 3Y7.04%
Revenue growth 5Y19.79%
Sales Q2Q%2.03%
Revenue Next Year4.9%
Revenue Next 2Y5.12%
Revenue Next 3Y5.4%
Revenue Next 5Y7.06%
EBIT growth 1Y-34.33%
EBIT growth 3Y9.68%
EBIT growth 5Y22.27%
EBIT Next Year-13.1%
EBIT Next 3Y1.4%
EBIT Next 5Y2.66%
FCF growth 1Y-115.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-108.03%
OCF growth 3YN/A
OCF growth 5YN/A
LHC GROUP INC / LHCG FAQ
What is the fundamental rating for LHCG stock?
ChartMill assigns a fundamental rating of 3 / 10 to LHCG.
Can you provide the valuation status for LHC GROUP INC?
ChartMill assigns a valuation rating of 1 / 10 to LHC GROUP INC (LHCG). This can be considered as Overvalued.
How profitable is LHC GROUP INC (LHCG) stock?
LHC GROUP INC (LHCG) has a profitability rating of 1 / 10.
What are the PE and PB ratios of LHC GROUP INC (LHCG) stock?
The Price/Earnings (PE) ratio for LHC GROUP INC (LHCG) is 38.68 and the Price/Book (PB) ratio is 3.29.
How financially healthy is LHC GROUP INC?
The financial health rating of LHC GROUP INC (LHCG) is 5 / 10.